Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies - Licenses (Details)

v3.3.1.900
Commitments and Contingencies - Licenses (Details)
$ in Millions
1 Months Ended 12 Months Ended
Mar. 31, 2015
USD ($)
person
Dec. 31, 2015
USD ($)
Dec. 31, 2014
Allergan      
Collaboration Revenue.      
Payment received to fund expansion of clinical trial $ 10.0    
Number of patients before expansion of the trial | person 500    
Number of patients after expansion of the trial | person 620    
Option agreement and a license agreement | Minimum      
Collaboration Revenue.      
Tiered royalties that could be received, as a percentage of net sales of licensed products   10.00%  
Option agreement and a license agreement | Maximum      
Collaboration Revenue.      
Tiered royalties that could be received, as a percentage of net sales of licensed products     20.00%
Option agreement and a license agreement | Allergan      
Collaboration Revenue.      
Consideration received upon the grant of the option   $ 0.0  
Aggregate potential consideration   365.0  
Option exercise fee   $ 65.0  
Term of royalty on sales from the first commercial sale of product   10 years